What are CYP450 Enzymes?

CYP450 enzymes are primarily expressed in the liver, where they perform Phase I metabolism — the chemical modification of drugs to make them more water-soluble for excretion. CYP3A4 alone metabolizes roughly 50% of all drugs, including statins, calcium channel blockers, HIV protease inhibitors, and immunosuppressants. CYP2D6 handles about 25% of drugs, including many antidepressants (fluoxetine, paroxetine), opioids (codeine, tramadol), and beta-blockers (metoprolol). CYP2C19 metabolizes proton pump inhibitors (omeprazole), antiplatelet drugs (clopidogrel), and antifungals (voriconazole). The clinical significance of these enzymes becomes apparent when genetic variants alter their activity.

Genetic polymorphisms in CYP genes create distinct metabolizer phenotypes: poor metabolizers (PM, no functional enzyme), intermediate metabolizers (IM, reduced activity), normal (extensive) metabolizers (NM/EM, typical activity), and ultrarapid metabolizers (UM, increased activity). CYP2D6 is the most polymorphic CYP gene, with over 130 known alleles. The *4 allele (rs3892097) is the most common non-functional allele in Europeans (frequency ~20-25%). CYP2C19*2 (rs4244285) causes poor metabolizer status in 2-5% of Europeans and 15-25% of Asians. These frequencies mean that a substantial portion of the population does not metabolize key drugs as expected, leading to either treatment failure or toxicity at standard doses.

For peptide therapeutics, CYP450 enzymes are less directly involved in drug metabolism because peptides are typically degraded by proteases rather than oxidized by CYPs. However, CYP450 pharmacogenomics remains relevant for two reasons. First, peptide drugs may be co-administered with CYP-metabolized conventional drugs, and understanding a patient's CYP profile helps avoid drug-drug interactions. Second, CYP variants can alter the metabolism of endogenous substrates (like hormones and signaling molecules) that influence the biological pathways targeted by therapeutic peptides. PepFold integrates CYP450 variant data into its holistic pharmacogenomic analysis to ensure peptide candidates are designed within the full context of a patient's metabolic profile.